Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ryder

141.64
+1.180.84%
Post-market: 141.30-0.3381-0.24%18:12 EDT
Volume:624.11K
Turnover:88.17M
Market Cap:5.91B
PE:12.81
High:142.48
Open:138.84
Low:138.67
Close:140.46
Loading ...

Press Release: Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Dow Jones
·
Yesterday

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
Yesterday

Press Release: MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Dow Jones
·
Yesterday

Press Release: Fifth Third Bancorp Announces Cash Dividends

Dow Jones
·
Yesterday

Press Release: Vetoquinol: Annual Results 2024

Dow Jones
·
Yesterday

Press Release: CVS Health declares quarterly dividend

Dow Jones
·
20 Mar

Press Release: FBI Veteran Joseph Bonavolonta Joins Wrap with 27 Years of Experience, Former SAC of Boston Field Office

Dow Jones
·
20 Mar

Press Release: Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Dow Jones
·
20 Mar

Press Release: Abeona Therapeutics(R) Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Dow Jones
·
20 Mar

Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends

Dow Jones
·
20 Mar

Press Release: InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Dow Jones
·
20 Mar

Press Release: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Dow Jones
·
20 Mar

Press Release: Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Dow Jones
·
20 Mar

Press Release: Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Dow Jones
·
20 Mar

Press Release: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
20 Mar

Press Release: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE(R) in Chronic Rhinosinusitis (CRS)

Dow Jones
·
20 Mar